Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta Post published:February 24, 2021 Post category:Press Release
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology Post published:February 17, 2021 Post category:Press Release
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Post published:February 12, 2021 Post category:Press Release
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Post published:February 3, 2021 Post category:Press Release
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Post published:February 1, 2021 Post category:Press Release
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland Post published:January 28, 2021 Post category:Press Release
Mydecine Innovations Group Files Application to list to the NASDAQ Post published:January 27, 2021 Post category:Press Release
Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units Post published:January 21, 2021 Post category:Press Release
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units Post published:January 14, 2021 Post category:Press Release
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer Post published:January 11, 2021 Post category:Press Release